[1] |
WU Yujie, ZHAO Chengcheng, XI Qing.
Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
|
[2] |
HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong.
Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
|
[3] |
ZHANG Huabin, LUO Zhongxu, ZHONG Min, HONG Zongyuan, WANG Deguo.
Study on the effect of spinal anesthesia on ventricular arrhythmias in acute myocardial ischemia-reperfusion in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 249-256.
|
[4] |
PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua.
Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
|
[5] |
CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke.
Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
|
[6] |
YANG Sheng, WANG Deguo.
Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
|
[7] |
GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing.
Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
|
[8] |
PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng.
Progress of pharmacotherapy for heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
|
[9] |
LIU Ping, QIU Bo, WU Huizhen.
Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218.
|
[10] |
ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng.
Model informed precision dosing of warfarin: China expert consensus report (2022 version)
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
|
[11] |
XU Liying, ZHANG Gaosong, HUANG Xiaomin, HUANG Jihan, WANG Shuhua.
Clinical efficacy and modeling evaluation of He-wei-zhi-xie capsules in treating diarrhea patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 47-55.
|
[12] |
XU Yonghua, SHI Xianghong.
Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
|
[13] |
JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan.
Model informed precision dosing: China expert consensus report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.
|
[14] |
LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun.
Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
|
[15] |
CHEN Lifang, WANG Bo, WANG Weirong.
Research advances of histone deacetylase 3 in cardiovascular diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97.
|